Arbutus Biopharma Corp. (ABUS)
4.45
-0.11
(-2.41%)
USD |
NASDAQ |
Oct 02, 16:00
4.475
+0.02
(+0.56%)
After-Hours: 20:00
Arbutus Biopharma PE Ratio : 5.680 for Oct. 2, 2026
PE Ratio Chart
Historical PE Ratio Data
| Date | Value |
|---|---|
| October 02, 2026 | 5.680 |
| October 01, 2026 | 5.821 |
| September 30, 2026 | 6.102 |
| September 29, 2026 | 5.987 |
| September 28, 2026 | 6.204 |
| September 25, 2026 | 6.191 |
| September 24, 2026 | 6.229 |
| September 23, 2026 | 6.191 |
| September 22, 2026 | 6.395 |
| September 21, 2026 | 6.382 |
| September 18, 2026 | 6.395 |
| September 17, 2026 | 6.472 |
| September 16, 2026 | 6.446 |
| September 15, 2026 | 6.459 |
| September 14, 2026 | 6.548 |
| September 11, 2026 | 6.536 |
| September 10, 2026 | 6.536 |
| September 09, 2026 | 6.599 |
| September 08, 2026 | 6.612 |
| September 04, 2026 | 6.574 |
| September 03, 2026 | 6.536 |
| September 02, 2026 | 6.510 |
| September 01, 2026 | 6.497 |
| August 31, 2026 | 6.485 |
| August 28, 2026 | 6.472 |
| Date | Value |
|---|---|
| August 27, 2026 | 6.599 |
| August 26, 2026 | 6.625 |
| August 25, 2026 | 6.638 |
| August 24, 2026 | 6.638 |
| August 21, 2026 | 6.650 |
| August 20, 2026 | 6.089 |
| August 19, 2026 | 6.357 |
| August 18, 2026 | 6.178 |
| August 17, 2026 | 6.012 |
| August 14, 2026 | 5.961 |
| August 13, 2026 | 5.846 |
| August 12, 2026 | 5.859 |
| August 11, 2026 | 5.961 |
| August 10, 2026 | 5.859 |
| August 07, 2026 | 5.910 |
| August 06, 2026 | 5.795 |
| August 05, 2026 | 5.897 |
| August 04, 2026 | 5.642 |
| August 03, 2026 | 5.566 |
| July 31, 2026 | 5.54 |
| July 30, 2026 | 5.629 |
| July 29, 2026 | 5.476 |
| July 28, 2026 | 5.629 |
| July 27, 2026 | 5.629 |
| July 24, 2026 | 5.591 |
PE Ratio Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS Diluted (TTM). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.
PE Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PE Ratio Benchmarks
| Insmed, Inc. | -- |
| Pfizer Inc. | 36.81 |
| Gossamer Bio, Inc. | -- |
| Legend Biotech Corp. | -- |
| ACADIA Pharmaceuticals, Inc. | 8.985 |
PE Ratio Related Metrics
| PS Ratio | 4.757 |
| Price to Book Value | 3.399 |
| Price | 4.45 |
| Earnings Yield | 17.60% |
| Market Cap | 879.47M |
| Operating PE Ratio | 5.863 |
| Normalized PE Ratio | 5.723 |